Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (321)	4/5/2002 4:08:49 PM
From: tuck	Respond to of 523

>>WASHINGTON -(Dow Jones)- Biotechnology Value Fund LP reported holding a 5.6% stake in Neurogen Corp. (NRGN), according to a Schedule 13G filed Friday with the Securities and Exchange Commission. On March 26 , Biotechnology Value Fund beneficially owned 984,249 Neurogen common shares. A Schedule 13G denotes a passive investment stake in a company. Filers aren't required to provide a reason for any changes in stake and aren't required to detail any transactions. Neurogen develops drugs that treat psychiatric and neurological disorders by regulating nerve cell communications in the brain.<< Cheers, Tuck